| 1 |
34969742 | Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma. | 2022 Jan |
2 |
| 2 |
35173295 | Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. | 2022 Feb 16 |
1 |
| 3 |
35351796 | Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. | 2022 May 17 |
1 |
| 4 |
35351965 | Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. | 2022 Mar 28 |
1 |
| 5 |
35452002 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. | 2022 Jul 1 |
2 |
| 6 |
33296093 | Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation. | 2021 Apr |
5 |
| 7 |
33400009 | Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide. | 2021 Jan |
1 |
| 8 |
33432322 | IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology. | 2021 Feb 22 |
2 |
| 9 |
33475680 | The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic. | 2021 May 1 |
1 |
| 10 |
33524191 | Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. | 2021 May |
4 |
| 11 |
33628600 | Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. | 2021 Feb 15 |
3 |
| 12 |
33823014 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. | 2021 Nov 2 |
1 |
| 13 |
33914057 | Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. | 2021 Sep 1 |
1 |
| 14 |
34067729 | From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. | 2021 May 17 |
4 |
| 15 |
34335021 | Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval. | 2021 |
1 |
| 16 |
34830935 | A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide. | 2021 Nov 18 |
1 |
| 17 |
34934580 | GammaTile Brachytherapy Combined With External Beam Radiation Therapy for the Treatment of a Partially Resected Secondary Glioblastoma (WHO Grade 4 IDH-Mutant Astrocytoma): Matching External Beam Dose Gradient to Brachytherapy Dose Fall-Off. | 2021 Nov |
2 |
| 18 |
32166314 | MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. | 2020 Nov 26 |
2 |
| 19 |
32942564 | XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma. | 2020 Sep 15 |
1 |
| 20 |
32958546 | Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. | 2020 Nov 15 |
4 |
| 21 |
33255358 | Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells. | 2020 Nov 24 |
1 |
| 22 |
30446361 | Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. | 2019 Jan |
1 |
| 23 |
30536544 | Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. | 2019 Jun 15 |
1 |
| 24 |
30771200 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. | 2019 May |
2 |
| 25 |
30863099 | Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review. | 2019 |
1 |
| 26 |
31443404 | Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma. | 2019 Aug 22 |
1 |
| 27 |
28887717 | Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. | 2018 Apr |
2 |
| 28 |
29393185 | Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. | 2018 |
1 |
| 29 |
29625108 | Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma. | 2018 May 23 |
1 |
| 30 |
29679127 | [Basic principles of diagnosis and treatment of gliomas]. | 2018 Jun |
1 |
| 31 |
29848907 | MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. | 2018 Jul 15 |
1 |
| 32 |
28202508 | Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. | 2017 Apr 1 |
1 |
| 33 |
28427200 | IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. | 2017 Apr 25 |
4 |
| 34 |
28571041 | CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. | 2017 Jun 27 |
1 |
| 35 |
28625978 | The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. | 2017 Aug 1 |
3 |
| 36 |
26911558 | IDH mutations may not preclude distant, trans-tentorial spread in gliomas: a case report and review of the literature. | 2016 Feb 24 |
1 |
| 37 |
26936071 | Systematic analysis of overall survival and interactions between tumor mutations and drug treatment. | 2016 Mar 2 |
2 |
| 38 |
27764705 | IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. | 2016 Dec |
4 |
| 39 |
25283382 | Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. | 2015 Feb |
4 |
| 40 |
26373279 | Spatiotemporal Evolution of the Primary Glioblastoma Genome. | 2015 Sep 14 |
2 |
| 41 |
24162810 | Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers. | 2014 Jan |
1 |
| 42 |
24305712 | Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. | 2014 Mar |
2 |
| 43 |
24748470 | IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. | 2014 Jun |
2 |
| 44 |
25035396 | Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. | 2014 Sep 1 |
6 |
| 45 |
22752663 | IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. | 2013 Apr |
1 |
| 46 |
22291938 | Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. | 2012 |
1 |
| 47 |
20975057 | IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. | 2010 Oct 26 |
1 |
| 48 |
19933982 | IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. | 2009 Nov 24 |
1 |